Trial Profile
A PHASE 3, MULTINATIONAL, RANDOMIZED, OPEN-LABEL, PARALLEL-ARM STUDY OF AVELUMAB (MSB0010718C) IN COMBINATION WITH AXITINIB (INLYTA) VERSUS SUNITINIB (SUTENT) MONOTHERAPY IN THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 19 Jan 2024
Price :
$35
*
At a glance
- Drugs Avelumab (Primary) ; Axitinib (Primary) ; Antihistamines; Paracetamol; Sunitinib
- Indications Renal cell carcinoma
- Focus Registrational; Therapeutic Use
- Acronyms JAVELIN Renal 101
- Sponsors Pfizer
- 19 Jan 2024 This trial has been completed in Denmark.
- 18 Jan 2024 This trial has been completed in Belgium.
- 01 Jan 2024 Results of post hoc analysis (n=412) assessing Impact of Prior Cytoreductive Nephrectomy on Efficacy in Patients with Synchronous Metastatic Renal Cell Carcinoma Treated with Avelumab plus Axitinib or Sunitinib published in the European Urology